PfizerPfizer's revenues for Q4 and the year announced last week are up 8% in 2020. Pfizer's $ 1.56 annual dividend payout currently corresponds to a 4.5% yield. These returns are well above the S&P 500 average.
As of February 2021, Pfizer has 95 completed projects, 24 of which are in phase 3. Pfizer expects 2021 to be a record year with revenues ranging from $ 60 billion to $ 61 billion. The COVID-19 vaccine business will be profitable consistently in 2021 and beyond.
The obvious risk today for Pfizer and the profitability of the pharmaceutical industry in general is the Biden administration's plans to reform healthcare and cut costs.
Based on current fundamentals, Pfizer shares should again bounce off $ 34 and may well reach $ 37 and $ 42, respectively.
Investment idea.
Share your opinion in the comments and support the idea with likes.
Thank you for your support!
